双重癌:左肺腺癌合并甲状腺内胸腺癌1例  

Double carcinoma:a case of left lung adenocarcinoma complicated with intrathyroid thymic carcinoma

作　　者：张胜波 范作兰 张健 张言敏[2] ZHANG Sheng-bo;FAN Zuo-lan;ZHANG Jian(Imaging Center of Gaomi People's Hospital,Weifang 261500,China)

机构地区：[1]山东省高密市人民医院影像中心,261500 [2]山东省高密市人民医院病理科,261500 [3]山东省高密市市立医院呼吸内科,261500

出　　处：《中国实用医药》2024年第15期161-163,共3页China Practical Medicine

摘　　要：多原发癌(MPC)又名重复癌,是指同一机体内同时或先后发生的两种或两种以上不相关的原发性恶性肿瘤。随着现代医学进步,多原发癌并不罕见,所有肿瘤患者的多原发恶性肿瘤(MPM)发病率约为0.73%~5.20%,这种广泛的差异与不同医院的医生和诊断工具不同有关。肺癌死亡率最高,由于低剂量肺癌筛查及人们健康意识的提高,大量早期肺癌被筛查出来,随着治疗方式的改进,如分子靶向治疗,使肺癌预后取得了大量进步,因此患者存活的时间足够长,可以发展为随后的原发肿瘤,但肺癌合并甲状腺内胸腺癌(ITTC)实属罕见。Multiple primary carcinoma(MPC),also known as duplicated carcinoma,refers to two or more unrelated primary malignant tumors occurring simultaneously or sequentially in the same organism.With modern medical advances,multiple primary carcinomas are not rare,and the prevalence of multiple primary malignant neoplasms(MPM)in all oncology patients is estimated to range from 0.73%to 5.20%,and this wide variation is associated with different experiences of doctors using different diagnostic tools and in different hospitals.Lung cancer has the highest mortality rate,and a large number of early stage lung cancers have been screened for due to low-dose lung cancer screening and increased health awareness.With improvements in treatment modalities,such as molecularly-targeted therapies,there have been a large number of advances in the prognosis of lung cancers,and as a result,patients are surviving long enough to develop subsequent primary tumors;however,lung cancers combined with intrathyroidal thymic carcinomas(ITTCs)are rare.

关 键 词：肺腺癌 甲状腺内胸腺癌 病理诊断 鉴别诊断 

分 类 号：R734.2[医药卫生—肿瘤] R736.1[医药卫生—临床医学]